{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-24T04:44:23.584Z","profile":{"slug":"mazdutide","name":"Mazdutide","aliases":[],"category":"GLP-1/glucagon receptor agonist"},"synthesis":{"mechanism":"Mazdutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic disease. Weight-management and type 2 diabetes trials have different enrolled populations, regimens, comparators, and endpoints.","evidence":"WPF’s atlas includes randomized-trial syntheses for overweight or obesity and comparisons with other incretin-pathway treatments. Meta-analyses and indirect network comparisons may combine heterogeneous studies; their titles do not establish comparative superiority or long-term benefit.","safety":"No published source-linked citations or jurisdiction-specific regulatory records have been attached here. Trial phase, population, dose, safety follow-up, and direct versus indirect comparison need source-level appraisal.","observationalBoundary":"WPF's separate observational archive may include contributor reports concerning mazdutide, used for weight management or type 2 diabetes. As with every entry in that archive, these de-identified reports can suggest questions but cannot establish causation, efficacy, comparative safety, or event frequency, and reports across these different use contexts should be interpreted separately.","openQuestions":"Which direct randomized trials support each investigated indication? How do effects and tolerability change by comparator and population? Which long-term outcomes remain uncertain?"},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":23,"evidenceDepth":"limited_evidence","complete":false,"checks":[{"key":"overview","passed":true,"actual":210,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":287,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":221,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":388,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":180,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":true,"actual":23,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":false,"actual":23,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":true,"actual":true,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":true,"actual":2,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["evidence_depth_target","reviewed_sources","claims"]},"chemistry":{"id":"22f40da7-2b8b-41b9-a8c6-83cac2164ab7","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","molecularFormula":"C207H317N45O65","molecularWeight":4476,"aminoAcidSequence":null,"smiles":"CC(C)CC(C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(C)(C)NC(=O)C(CC8=CNC=N8)N","inchi":"InChI=1S/C207H317N45O65/c1-116(2)93-144(189(295)230-138(70-76-168(271)272)179(285)221-107-162(264)219-109-166(268)252-86-46-57-157(252)201(307)245-154(110-253)181(287)220-106-159(213)261)234-190(296)145(94-117(3)4)236-194(300)151(100-127-104-218-133-52-37-36-51-131(127)133)240-188(294)142(73-79-171(277)278)233-202(308)174(119(7)8)249-197(303)149(96-123-47-30-28-31-48-123)238-187(293)141(72-78-170(275)276)231-183(289)135(56-41-45-83-215-164(266)113-316-91-90-315-88-85-217-165(267)114-317-92-89-314-87-84-216-160(262)75-69-143(205(311)312)225-161(263)58-34-26-24-22-20-18-16-14-15-17-19-21-23-25-27-35-59-167(269)270)226-177(283)120(9)224-182(288)134(53-38-42-80-208)227-184(290)136(54-39-43-81-209)228-186(292)140(71-77-169(273)274)232-195(301)152(102-172(279)280)241-191(297)146(95-118(5)6)235-192(298)147(98-125-60-64-129(258)65-61-125)237-185(291)137(55-40-44-82-210)229-199(305)155(111-254)244-193(299)148(99-126-62-66-130(259)67-63-126)239-196(302)153(103-173(281)282)242-200(306)156(112-255)246-204(310)176(122(11)257)250-198(304)150(97-124-49-32-29-33-50-124)243-203(309)175(121(10)256)248-163(265)108-222-180(286)139(68-74-158(212)260)247-206(313)207(12,13)251-178(284)132(211)101-128-105-214-115-223-128/h28-33,36-37,47-52,60-67,104-105,115-122,132,134-157,174-176,218,253-259H,14-27,34-35,38-46,53-59,68-103,106-114,208-211H2,1-13H3,(H2,212,260)(H2,213,261)(H,214,223)(H,215,266)(H,216,262)(H,217,267)(H,219,264)(H,220,287)(H,221,285)(H,222,286)(H,224,288)(H,225,263)(H,226,283)(H,227,290)(H,228,292)(H,229,305)(H,230,295)(H,231,289)(H,232,301)(H,233,308)(H,234,296)(H,235,298)(H,236,300)(H,237,291)(H,238,293)(H,239,302)(H,240,294)(H,241,297)(H,242,306)(H,243,309)(H,244,299)(H,245,307)(H,246,310)(H,247,313)(H,248,265)(H,249,303)(H,250,304)(H,251,284)(H,269,270)(H,271,272)(H,273,274)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H,311,312)/t120-,121+,122+,132-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,174-,175-,176-/m0/s1","inchikey":"XRBYWQZGSZWYEJ-HMQIFOERSA-N","structureImageUrl":"https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/167312357/PNG","createdAt":"2026-09-23T02:36:54.101Z","updatedAt":"2026-09-23T02:36:54.101Z"},"evidence":[{"id":"6691438b-e5ad-4915-a7f2-66d72abdf2ad","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41804840/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.\" Abstract excerpt: Mazdutide, a dual GLP-1 and glucagon receptor agonist, shows promise for weight loss and glycaemic control. This study evaluates its efficacy in non-diabetic patients with obesity. A search of Cochrane Library, PubMed, Google Scholar and clinicaltrials.gov identified randomised controlled trials (RCTs) of mazdutide in adults (≥ 18 years) with obesity. Meta-analysis was performed using RevMa","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1111/dom.70643","pubmedId":"41804840","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=4). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/dom.70643","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.833Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"8e136457-8a21-435d-8159-94de8711ca6e","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42410325/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.\" Abstract excerpt: To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D). This systematic review and meta-analysis included randomized controlled trials (RCTs) comparing mazdutide with placebo or active comparators in adults with overweight/obesity and/or T2D, identified through PubMed, Scopus, Web of Science, a","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1111/dom.71058","pubmedId":"42410325","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=25, totalMentions=6). Imported evidence lane: synthesis. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/dom.71058","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.424Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"441cf0ed-601b-4cf5-8e43-2b52384a517f","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42628555/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.\" Abstract excerpt: Therapies targeting GLP-1 or glucose-dependent insulinotropic polypeptide (GIP) receptors have provided efficacious weight reduction in adults with obesity. Mazdutide, a glucagon and GLP-1 receptor dual agonist, presents a novel opportunity for differentiated weight reduction. We aimed to evaluate the efficacy, safety, and tolerability of once-weekly mazdutide across a dose range up to 16 mg in ad","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/s2213-8587(26)00160-9","pubmedId":"42628555","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=157, totalMentions=8). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/s2213-8587(26)00160-9","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.757Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"2951dbe4-bbbe-4851-bc17-919bc4e125d2","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41875890/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m<sup>2</sup> but without diabetes: A phase 2 randomized controlled trial.\" Abstract excerpt: Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity. In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body m","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/j.medj.2026.101063","pubmedId":"41875890","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=71, totalMentions=10). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.medj.2026.101063","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.041Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"1ebbffbb-95ff-460d-a778-3340b52525c4","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41901218/","evidenceTier":"animal","summary":"Content-verified record concerning Mazdutide: \"Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.\" Abstract excerpt: Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disorder globally. Mazdutide has shown clinical benefits in weight management and metabolic regulation, indicating its potential as a therapeutic agent for MASLD. This study aimed to investigate the efficacy and mechanism of action of Mazdutide against early-stage MASLD. Methods: A MASL","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.3390/ph19030371","pubmedId":"41901218","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=132, totalMentions=7). Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3390/ph19030371","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.376Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"94db40df-0c95-4886-86a6-ad01a5d1de78","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251768/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1001/jama.2026.10443","pubmedId":"42251768","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: commentary genuinely discussing mazdutide (jointly with a second compound); not yet MEDLINE-indexed.. Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1001/jama.2026.10443","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:34.992Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"35562f05-25e9-4ffd-b772-9474d4709630","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41260459/","evidenceTier":"phase_3","summary":"Content-verified record concerning Mazdutide: \"Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.\" Abstract excerpt: Effective weight management and glycemic control are both important in people with type 2 diabetes (T2D) and obesity. Despite the proven benefits of GLP-1 receptor agonists, there is a persistent need for more effective weight management strategies in the treatment of T2D and obesity. Glucagon receptor-based co-agonists, such as mazdutide, represent a promising therapeutic class with the potential","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1016/j.cct.2025.108150","pubmedId":"41260459","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=331, totalMentions=4). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.cct.2025.108150","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:16.925Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"c68147ad-0c92-4470-afec-126acca6f214","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41407860/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.\" Abstract excerpt: Mazdutide is a once-weekly glucagon and glucagon-like peptide 1 receptor dual agonist developed for the treatment of type 2 diabetes (T2D) 1 . Here we report on a randomized phase III trial assessing the efficacy and safety of mazdutide, compared with dulaglutide, in participants with T2D who were also treated with background oral anti-diabetic drugs. In this study, 731 participants with T2D were ","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1038/s41586-025-10031-z","pubmedId":"41407860","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=14). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s41586-025-10031-z","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.234Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"6acf0b07-0a80-441b-9118-691af9eb1248","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide versus placebo in Chinese adults with type 2 diabetes.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41407859/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Mazdutide versus placebo in Chinese adults with type 2 diabetes.\" Abstract excerpt: Despite advances in type 2 diabetes (T2D) management, unmet needs remain for therapies that effectively control hyperglycaemia while addressing comorbid metabolic disorders 1,2 . Here we assessed the efficacy and safety of the dual glucagon receptor (GCGR)/glucagon-like peptide-1 receptor (GLP-1R) agonist mazdutide monotherapy versus placebo in Chinese adults with T2D controlled inadequately with ","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1038/s41586-025-10026-w","pubmedId":"41407859","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=307, totalMentions=8). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s41586-025-10026-w","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.113Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"3d86b56d-6844-45a4-9917-fc61d60438fb","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41820018/","evidenceTier":"animal","summary":"Content-verified record concerning Mazdutide: \"Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.\" Abstract excerpt: Mazdutide is a dual glucagon-like peptide-1 receptor (GLP-1 R) and glucagon receptor (GCGR) agonist representing a new generation of incretin-based therapeutics for obesity and type 2 diabetes. While its clinical efficacy is increasingly recognized, the intellectual property framework that underpins its development and long-term positioning has not been systematically examined. This review present","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1080/13543776.2026.2645812","pubmedId":"41820018","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=3). Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1080/13543776.2026.2645812","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.166Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"c28cbf75-9a06-4da1-804b-1637a69e3046","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251596/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: Research Summary.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1001/jama.2026.8427","pubmedId":"42251596","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: plain-language summary of a specific mazdutide trial; not yet MEDLINE-indexed.. Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1001/jama.2026.8427","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:35.147Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"6f1400e0-7a64-44fa-aab1-40925dd2806c","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/42251595/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.\" Abstract excerpt: Obesity is a worldwide problem and a major public health issue in China. To evaluate the efficacy and safety of mazdutide (a once-weekly glucagon and glucagon-like peptide-1 receptor dual agonist) in Chinese adults with obesity (defined as a body mass index of ≥30). A double-blind, placebo-controlled, phase 3, randomized clinical trial including Chinese adults with or without type 2 diabete","authors":null,"publishingOrg":null,"publicationYear":2026,"doi":"10.1001/jama.2026.8142","pubmedId":"42251595","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=112, totalMentions=8). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1001/jama.2026.8142","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.641Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"ca685eb5-08db-46e8-951d-f9d3704663f6","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41030857/","evidenceTier":"observational","summary":"Content-verified record concerning Mazdutide: \"Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.\" Abstract excerpt: Mazdutide, a glucagon-like peptide-1/glucagon receptor (GLP - 1/GCGR) dual agonist, has shown marked efficacy in glycemic control, weight loss, and metabolic improvement in adults. However, data in adolescents remain limited. This report explores its therapeutic potential in an adolescent with obesity-related type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA). We report the case of a 15-year-","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.3389/fendo.2025.1654506","pubmedId":"41030857","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=3). Imported evidence lane: human_observational. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3389/fendo.2025.1654506","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.283Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"a5d89280-b75c-41d2-9da4-b2fad9c6fb40","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40832785/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.\" Abstract excerpt: Mazdutide, an agonist of glucagon-like peptide-1 and glucagon receptors, significantly reduced weight in early phase trials at doses up to 10 mg. This randomized, double-blind, placebo-controlled Phase 1 trial evaluated the safety and efficacy of mazdutide up to 16 mg in adults with overweight or obesity. Thirty-two adults with overweight/obesity without diabetes received once-weekly subcutaneous ","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1111/dom.70040","pubmedId":"40832785","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=6). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1111/dom.70040","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.304Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"607b06b8-5b9a-4c20-b61e-d7d5187a7891","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40479843/","evidenceTier":"animal","summary":"Content-verified record concerning Mazdutide: \"Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.\" Abstract excerpt: Cognitive impairment and dementia are highly associated with obesity and type 2 diabetes mellitus (T2DM). Recent studies have demonstrated that GLP-1 receptor agonists can improve cognitive function through brain activation in patients with T2DM, compared to other oral glucose-lowering drugs. Mazdutide, a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1016/j.ebiom.2025.105791","pubmedId":"40479843","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=294, totalMentions=8). Imported evidence lane: preclinical_animal. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.ebiom.2025.105791","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.449Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"1af86cff-7f22-4698-b7af-1b45ad73fcd0","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide: First Approval.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/41028652/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Mazdutide: First Approval.\" Abstract excerpt: Mazdutide (Xinermei ® ) is a dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist being developed by Eli Lilly and Company along with Innovent Biologics for use in weight management in adults with obesity or overweight and for the treatment of type 2 diabetes (T2D). In June 2025, mazdutide received its first approval, in China, for use (in combination with ","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1007/s40265-025-02249-y","pubmedId":"41028652","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=5). Imported evidence lane: synthesis. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1007/s40265-025-02249-y","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.566Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"cc0a612e-cdbc-4b58-aa6c-096f7010c2f5","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40421736/","evidenceTier":"insufficient","summary":"Direct clinical study in its enrolled adult population; does not establish outcomes beyond its design.","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1056/nejmoa2411528","pubmedId":"40421736","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Upgraded from an entered/unverified draft to a content-verified citation. Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=103, totalMentions=12). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":"This publication addresses Mazdutide in the specific setting identified in its title.","supportNature":"Screened source-level context; specific outcomes and evidence tier await appraisal.","qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmoa2411528","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T02:12:45.593Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"f35a9408-a8e9-4d20-b8e3-5cb13327f663","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Once-Weekly Mazdutide in Obesity or Overweight. Reply.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/40929642/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Once-Weekly Mazdutide in Obesity or Overweight. Reply.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2025,"doi":"10.1056/nejmc2509841","pubmedId":"40929642","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: Read directly: author reply in a correspondence thread specifically about mazdutide's own trial; not yet MEDLINE-indexed.. Imported evidence lane: contextual_unclassified. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1056/nejmc2509841","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T23:11:35.070Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"47d79cd4-322b-4463-b4e8-b7ba1542f4a7","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/37943529/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.\" Abstract excerpt: We conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the efficacy and safety of mazdutide, a once-weekly glucagon-like peptide 1 and glucagon receptor dual agonist, in Chinese patients with type 2 diabetes. Adults with type 2 diabetes inadequately controlled with diet and exercise alone or with stable metformin (glycated hemoglobin A1c [HbA1c] 7.0-10.5% [53-91 mmol","authors":null,"publishingOrg":null,"publicationYear":2024,"doi":"10.2337/dc23-1287","pubmedId":"37943529","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=113, totalMentions=9). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.2337/dc23-1287","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.904Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"637421ee-fec8-471f-9b0c-b6de16af68b0","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38440786/","evidenceTier":"insufficient","summary":"Content-verified record concerning Mazdutide: \"Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.\" Abstract excerpt: Overweight and obesity are increasing global public health problems. Mazdutide is a new dual agonist drug that can potentially reduce weight and blood glucose levels simultaneously. However, the synthesis of evidence on the efficacy and safety of this drug is scarce. Therefore, this study aimed to synthesize evidence on the efficacy and safety of Mazdutide compared to placebo on weight reduction a","authors":null,"publishingOrg":null,"publicationYear":2024,"doi":"10.3389/fendo.2024.1309118","pubmedId":"38440786","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: systematic review or meta-analysis. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=69, totalMentions=5). Imported evidence lane: synthesis. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"systematic_review_or_meta_analysis","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.3389/fendo.2024.1309118","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:17.977Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"353fd093-2226-4adb-a667-16235d06c37f","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/39292847/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.\" (identity confirmed; no abstract text available to excerpt.)","authors":null,"publishingOrg":null,"publicationYear":2024,"doi":"10.1097/mjt.0000000000001756","pubmedId":"39292847","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: pubmed_curated_indexing_confirms_subject (matched: \"mazdutide\"). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1097/mjt.0000000000001756","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:44:19.085Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"38c08870-e137-4dc7-a39a-77bf03ac086d","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/38092790/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.\" Abstract excerpt: Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT0490","authors":null,"publishingOrg":null,"publicationYear":2023,"doi":"10.1038/s41467-023-44067-4","pubmedId":"38092790","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=7). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1038/s41467-023-44067-4","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.091Z","updatedAt":"2026-09-23T23:29:32.913Z"},{"id":"e21d41a3-68ae-4f58-b019-350e166c2392","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.","sourceUrl":"https://pubmed.ncbi.nlm.nih.gov/36247927/","evidenceTier":"phase_1_2","summary":"Content-verified record concerning Mazdutide: \"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.\" Abstract excerpt: Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. We further explored the safety and efficacy of mazdutide dosed up to 9 mg and 10 mg. In this randomised, placebo-controlled, multiple-ascending-dose phase","authors":null,"publishingOrg":null,"publicationYear":2022,"doi":"10.1016/j.eclinm.2022.101691","pubmedId":"36247927","jurisdiction":null,"dateAccessed":null,"editorialNotes":"Category: primary research record. Verified by content, not title or identifier alone: abstract_confirms_peptide_as_subject (firstMentionChar=0, totalMentions=12). Imported evidence lane: human_interventional. Source provider: Europe PMC. Content-verified for the 13-profile directory completion effort (2026-09) using free NCBI PubMed E-utilities; no paid API used.","sourceType":"peer_reviewed_research","claimSupported":null,"supportNature":null,"qualification":null,"verificationStatus":"verified","publicationStatus":"published","addedById":null,"machineActor":"wpf-directory-completion-content-verified-2026-09","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","canonicalSourceIdentity":"doi:10.1016/j.eclinm.2022.101691","sourceIdentityId":null,"sourceStatus":"active","sourceContentHash":null,"sourceVersion":1,"retrievedAt":null,"retrievalProvider":null,"retrievalPayloadRef":null,"evidenceLane":null,"extractionPayload":null,"provenancePayload":null,"validationGates":null,"engineState":"manual","engineRunId":null,"createdAt":"2026-09-23T22:29:18.352Z","updatedAt":"2026-09-23T23:29:32.913Z"}],"regulatory":[{"id":"98e379e0-c41d-469d-8870-2bb62d3562ea","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","jurisdiction":"China — NMPA","status":"approved","approvedIndication":"Mazdutide is approved by China's National Medical Products Administration for chronic weight management in adults with obesity or overweight (approved 2025-06-27), and separately for glycemic control in adults with type 2 diabetes (approved 2025-09-19).","rationale":"Innovent Biologics' official announcements document two separate NMPA marketing approvals for mazdutide in China: chronic weight management (June 2025) and type 2 diabetes glycemic control (September 2025). This status is specific to China and does not extend to the United States or European Union, where mazdutide remains investigational.","sourceTitle":"Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management","sourceUrl":"https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.800Z","updatedAt":"2026-09-23T23:29:32.990Z"},{"id":"b82b29e5-6b0e-4718-a3c0-3d7697690157","peptideId":"5500bee9-eb0c-4bbb-9f45-195ccef9a423","jurisdiction":"United States — FDA","status":"not_approved","approvedIndication":null,"rationale":"No FDA-approved product containing mazdutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Mazdutide is approved in China (see the China — NMPA entry on this profile) but remains investigational in the United States, where it has not completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific.","sourceTitle":"FDA Drugs@FDA database","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/","dateChecked":"2026-09-23T00:00:00.000Z","reviewDueAt":"2026-12-22T00:00:00.000Z","enteredById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","reviewedById":"0bf5b853-ea8b-4aa3-bffe-2af0fdd75150","publicationStatus":"published","factualObservationId":null,"createdAt":"2026-09-23T02:42:18.724Z","updatedAt":"2026-09-23T23:29:32.990Z"}],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}